One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Purpose: Neuroendocrine tumors (NETs) are considered rare tumors and can produce a variety of hormones. In this study, we examined the epidemiology of and prognostic factors for NETs, because a thorough examination of neither had previously been performed. Methods: The Surveillance, Epidemiology, and End Results (SEER) Program registries were searched to identify NET cases from 1973 to 2004. Associated population data were used for incidence and prevalence analyses. Results: We identified 35,618 patients with NETs. We observed a significant increase in the reported annual age-adjusted incidence of NETs from 1973 (1.09/100,000) to 2004 (5.25/100,000). Using the SEER 9 registry data, we estimated the 29-year limited-duration prevalence of NETs on January 1, 2004, to be 9,263. Also, the estimated 29-year limited-duration prevalence in the United States on that date was 103,312 cases (35/100,000). The most common primary tumor site varied by race, with the lung being the most common in white patients, and the rectum being the most common in Asian/Pacific Islander, American Indian/Alaskan Native, and African American patients. Additionally, survival duration varied by histologic grade. In multivariate analysis of patients with well-differentiated to moderately differentiated NETs, disease stage, primary tumor site, histologic grade, sex, race, age, and year of diagnosis were predictors of outcome (P < .001). Conclusion: We observed increased reported incidence of NETs and increased survival durations over time, suggesting that NETs are more prevalent than previously reported. Clinicians need to be become familiar with the natural history and patterns of disease progression, which are characteristic of these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,805
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
Carcinoid TumorsAn analysis of 2837 cases
Godwin, J. D. (1975) · Cancer · doi:10.1002/1097-0142(197508)36:2<560::aid-cncr2820360235>3.0.co;2-4 · Cited by 1,106
Kulke, M. H., & Mayer, R. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903183401107 · Cited by 741
Karzinoide Tumoren des Dunndarms
Oberndorfer, S. (1907) · Medical Entomology and Zoology · Cited by 578
Population-Based Study of Islet Cell Carcinoma
Yao, J. C., Eisner, M. P., Leary, C., Dagohoy, C., Phan, A., Rashid, A., Hassan, M., & Evans, D. B. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9566-6 · Cited by 338
Self-citationCarcinoid A Comprehensive Review
Schnirer, I. I., Yao, J. C., & Ajani, J. A. (2003) · Acta Oncologica · doi:10.1080/02841860310010547 · Cited by 192
Self-citationSurvival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based Study
Lepage, C., Rachet, B., & Coleman, M. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.006 · Cited by 129
Molecular targeted therapy for carcinoid and islet-cell carcinoma
Yao, J. C. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.01.006 · Cited by 115
Self-citationGail, M. H., Kessler, L., Midthune, D., & Scoppa, S. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.01137.x · Cited by 51
The prevalence of cancer among adults in the United States: 1987
Byrne, J., Kessler, L. G., & Devesa, S. S. (1992) · Cancer · doi:10.1002/1097-0142(19920415)69:8<2154::aid-cncr2820690823>3.0.co;2-r · Cited by 50
Treatment of neuroendocrine tumors
Öberg, K. (1994) · Cancer Treatment Reviews · doi:10.1016/0305-7372(94)90016-7 · Cited by 32
Estimating the variance of cancer prevalence from population-based registries
Gigli, A., Mariotto, A. B., Clegg, L. X., Tavilla, A., Corazziari, I., Capocaccia, R., Hachey, M., & Scoppa, S. (2006) · Statistical Methods in Medical Research · doi:10.1191/0962280206sm427oa · Cited by 22
Cited by
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,447
Self-citationPhase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
“Decreased appetite 20 (18) 0 9 (8) 3 (3) 0.”
Self-citationEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Self-citationLanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Metadata
- Authors
- Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., & Evans, D. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-06-20
- Volume
- 26
- Issue
- 18
- Pages
- 3063-3072
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149214723
- Cited by
- 4,510
- References
- 13
- FWCI
- 62.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.